Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling
The therapy was also generally well tolerated, with mostly mild injection-site reactions and no increased risk of serious infections, thrombosis, or cardiovascular events
If symptoms are ongoing, your clinician may adjust the dose, timing, or switch medicines
Researchers who have experience with semaglutide dosing or tirzepatide dosing sometimes assume that retatrutide titration can be more aggressive because of their prior experience with GLP-1 receptor activation
Studies show that between 40 to 70% of people experience gastrointestinal issues such as nausea, vomiting, diarrhea, constipation, and bloating
Payers are talking about this because its impacting everyone